Business Context and Reporting Period
Company: Alumis Inc. (ALMS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune disorders. Its lead product candidate is envudeucitinib ("envu"), a second-generation TYK2 inhibitor for moderate-to-severe plaque psoriasis (PsO). The company also has a pipeline candidate, A-005, and acquired lonigutamab (for Thyroid Eye Disease) via the ACELYRIN Merger completed in May 2025.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $1,741 | $17,389 |
| Net Loss | $(93,053) | $(98,963) |
| Loss Per Share (Basic & Diluted) | $(0.74) | $(1.82) |
| Operating Expenses | $100,150 | $118,917 |
| Research & Development (R&D) | $81,540 | $96,622 |
| General & Administrative (G&A) | $18,610 | $22,295 |
| Cash, Cash Equivalents & Marketable Securities | $569,543 | $308,583 |
| Accumulated Deficit | $(994,929) | $(757,514) |
Note: Revenue in Q1 2025 included a one-time license revenue recognition of $17.4 million from the Kaken Collaboration Agreement. Q1 2026 revenue consists primarily of collaboration revenue ($1.7 million).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 90% ($15.6 million) compared to Q1 2025, primarily due to the recognition of the $17.4 million upfront license fee in the prior year. Current revenue is driven by collaboration services.
- Expense Reduction: Total operating expenses decreased by 16% ($18.8 million). R&D expenses dropped 16% ($15.1 million), largely due to lower clinical trial and CRO costs following the completion of enrollment in pivotal Phase 3 trials for envu. G&A expenses decreased 17% ($3.7 million), driven by the absence of ACELYRIN Merger transaction costs incurred in the prior year.
- Capital Raise: In January 2026, the company completed a public offering of common stock, raising net proceeds of approximately $324.4 million. This significantly increased cash and marketable securities balances.
- Net Loss Improvement: Net loss narrowed by 6% ($5.9 million) to $93.1 million, despite lower revenue, due to the significant reduction in operating expenses.
Guidance, Outlook, and Risks
- Development Milestones: The company plans to submit a New Drug Application (NDA) for envu in PsO to the FDA in the second half of 2026. Topline results for the Phase 3 ONWARD1 and ONWARD2 trials were reported as positive in Q1 2026. Topline results for the Phase 2b trial in systemic lupus erythematosus (SLE) are expected in Q3 2026.
- Strategic Review: In May 2026 (subsequent to the reporting period), the company completed a strategic review of the lonigutamab program and decided to explore strategic alternatives. This may trigger an interim impairment assessment of the $51.0 million acquired IPR&D intangible asset.
- Liquidity: Management believes existing cash, cash equivalents, and marketable securities of $569.5 million are sufficient to fund operations for at least 12 months from the filing date. The company entered into an "at-the-market" (ATM) sales agreement in March 2026 to sell up to $300 million of common stock.
- Legal Contingencies: The company is a defendant in a purported federal securities class action lawsuit (Boukadoum v. Acelyrin, Inc.) related to the Phase 2b trial of izokibep. A motion to dismiss the second amended complaint remains pending. No liability has been accrued as the outcome is uncertain.
- Macroeconomic Risks: The company faces risks related to global tariffs (including a potential 100% tariff on certain patented pharmaceuticals announced in April 2026), geopolitical tensions, and supply chain disruptions.
Investor Verification Checklist
- NDA Submission Timeline: Verify the company's ability to meet the H2 2026 NDA submission target for envu in PsO, given the complexity of regulatory requirements.
- Lonigutamab Impairment: Monitor for potential impairment charges related to the $51.0 million IPR&D asset following the decision to explore strategic alternatives for the lonigutamab program.
- Capital Requirements: Assess the burn rate relative to the $569.5 million cash position to determine if additional financing will be needed before the 12-month liquidity horizon.
- Legal Proceedings: Track the status of the securities class action lawsuit and any potential settlement costs or reputational impact.
- Revenue Recognition: Understand the timing of future revenue recognition under the Kaken Collaboration Agreement, specifically regarding development cost reimbursements and potential milestones.